Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.

http://www.wikidata.org/entity/Q37179450

about

Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229).Plasma concentration of metformin and dexamethasone after administration through Osseogate.

P2860

Q51373715-69B98998-A845-403F-BA2C-870D937A6317 Q53122341-6FA0DC38-E34D-49C1-8362-34F1C89DD19C

P2860

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.

http://www.wikidata.org/entity/Q37179450

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacokinetic and pharmacody ...... ogliptin, in healthy subjects.

@en

Pharmacokinetic and pharmacody ...... ogliptin, in healthy subjects.

@nl

type

label

Pharmacokinetic and pharmacody ...... ogliptin, in healthy subjects.

@en

Pharmacokinetic and pharmacody ...... ogliptin, in healthy subjects.

@nl

prefLabel

Pharmacokinetic and pharmacody ...... ogliptin, in healthy subjects.

@en

Pharmacokinetic and pharmacody ...... ogliptin, in healthy subjects.

@nl

P1433

Q37179450-D3A0FC16-AC5B-42A5-AE35-FD963F29C728

P1476

Q37179450-85933962-C1CD-4AC9-85B2-95D945979256

P2093

Q37179450-3AAAD7B8-235F-4E0D-9EF3-5F27FADE635F

Q37179450-7AF9954B-3163-4AD1-84E8-8779456718F6

Q37179450-9B3A8CA4-E8D4-464F-ABFA-302A0E7D9311

Q37179450-9EFD6F32-5172-41B3-8D4B-FB7C461307B3

Q37179450-CF331721-2310-490C-AFB9-40670BF23F8F

Q37179450-F02DDB2C-8064-48C2-AA8B-41AAE980CC40

P2860

Q37179450-146BDA45-C5C2-4ACA-A3D4-B75A470D2F23

Q37179450-36EEAC7A-58D7-41A0-9DCC-2175D8F46464

Q37179450-4AAA5019-5912-4BF7-89CB-E4900B514CAA

Q37179450-55869C3B-02D6-4E1C-A8BE-7AC0E34E0422

Q37179450-55D4AEB4-AD30-4A09-91A7-D0D55F7E3774

Q37179450-5F46DB5E-30D8-4416-8F86-8AD5E00DF6F6

Q37179450-7AAC9EA6-DA36-433F-B964-4F0BF5997B43

Q37179450-8D083AA6-3B65-4136-A540-4C7831C041CF

Q37179450-98515499-8418-44DD-9460-03CF73A19432

Q37179450-CB7B17DF-397D-4290-8DC8-05BCEEF8B6F1

P304

Q37179450-A5C75357-3138-4DA2-8CF1-488F5E7447B7

P31

Q37179450-14B20599-F21A-4671-9E7A-C1FA01A27409

P356

Q37179450-5C308D2B-5C67-45A2-868E-D942AA9D167D

P407

Q37179450-5FECC703-FAB5-4DEB-9E2C-B660AD9890B4

P478

Q37179450-E8996814-6837-42F0-86CE-F0B2E09BFC32

P50

Q37179450-6E62BFC0-1080-4BCD-B9CE-CA2F3BD427CA

Q37179450-9633D0BD-CAE6-4415-9225-DBFD3577ED39

P577

Q37179450-8888E184-881E-4298-8C06-C1D5F90EBB62

P698

Q37179450-02C425D0-56B7-4792-9366-F717466EBABD

P921

Q37179450-6E11108D-F357-4043-BCDD-7DB9BAF529AB

P932

Q37179450-03B16069-CA00-4472-BFF5-096353971D2D

P356

P1433

Drug Design, Development and Therapy

P1476

Pharmacokinetic and pharmacody ...... vogliptin, in healthy subjects

@en

P2093

Kyung-Sang Yu

http://www.w3.org/2001/XMLSchema#string

Seo Hyun Yoon

http://www.w3.org/2001/XMLSchema#string

SeungHwan Lee

http://www.w3.org/2001/XMLSchema#string

Su-Jin Rhee

http://www.w3.org/2001/XMLSchema#string

Sung-Jin Kim

http://www.w3.org/2001/XMLSchema#string

YoonJung Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Pharmacokinetics of Metformin

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus.

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.

P304

2525-2534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S110712

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27570447

http://www.w3.org/2001/XMLSchema#string

P921

P932

4986685

http://www.w3.org/2001/XMLSchema#string